Ecallantide

Treats acute attacks of hereditary angioedema (HAE). Sold as Kalbitor. Every FDA application for this active ingredient.

As of Nov 13, 2026, FDA lists 1 application for Ecallantide (sold as Kalbitor), first approved Dec 1, 2009, with 1 new use approved and 0 published complete response letters.

First approved: Dec 1, 2009
Applications: 1
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $19.0M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Kalbitor	Part D	$19.0M	-9%	31

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Dec 1, 2009	KalbitorBLA 125277 · New molecular entity	Dyax Corp.	7	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA